Structural Genomics Consortium

Founded in 2004, the Structural Genomics Consortium (SGC) is a registered UK-based charity composed of a global public-private partnership, with head offices in Toronto. Dedicated to open science, the SGC accelerates the distribution of new medicines by making information about human genes and proteins available in the public domain. The collaboration among a large network of scientists in academia and industry allows for all research outputs to be openly available to the scientific community. The SGC has approximately 200 scientists in six major research labs at universities in Canada, the United States, and Europe, with the largest site located at the University of Toronto. Our partners include several global pharmaceutical companies, government institutions and foundations. By adhering to a global open science model, the SGC is leading the way towards drug discovery solutions. The organization’s focus has evolved from structure-guided drug discovery, towards identifying chemical probes for understudied protein families in the human genome. In using the open science model of offering data patent-free, the chemical probes can be used by researchers all over the world as tools to unlock new areas of disease biology, supporting the identification of new proteins that are likely to lead to cures and treatments for common diseases like cancer, Alzheimer’s disease, Parkinson’s disease, and rare diseases too.

‍